Hunan Warrant Pharmaceutical Co., Ltd, a pharmaceutical company based in China and listed on the Shanghai Stock Exchange’s Science and Technology Innovation Board (SHA: 688799), has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 drug candidate, ZG-002. This new molecule is intended for evaluation as a treatment for patients suffering from moderate to severe plaque psoriasis.
ZG-002 is a TYK2 allosteric inhibitor, a novel approach to treating autoimmune diseases. In vitro pharmacological studies have highlighted its superior inhibitory activity against TYK2, coupled with high selectivity. The drug candidate has shown promising results in a classic animal model of psoriasis, indicating good therapeutic effects. ZG-002’s profile includes not only robust in vitro and in vivo activity but also excellent metabolic properties and a strong safety profile, positioning it as a potential new option for psoriasis treatment.- Flcube.com
